Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time.
During the event, Chemomab's management team will review second quarter 2022 performance, discuss recent and upcoming developments and conduct a live question-and-answer session.
A replay of the call will be available on Chemomab's website for 90 days at www.chemomab.com.
Live Webcast and Conference Call at 8:00 am Eastern Time, Friday, August 12, 2022
Click this Webcast link to access the live webcast or replay.
The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events.
Conference Call Access via Telephone
US Investors: +1 (877) 407-9208
International Investors: +1 (201) 493-6784
Conference Passcode: 13730646
Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.
Chemomab is a clinical stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in late 2022. For more information, visit chemomab.com.
Contacts:
Investor Relations: | Media: |
Irina Koffler | Barbara Lindheim |
LifeSci Advisors, LLC | Chemomab Therapeutics |
Phone: +1 (917) 734-7387 | Consulting Vice President |
This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor & Public Relations, |
Strategic Communications | |
Phone: +1 (917) 355-9234 | |
This email address is being protected from spambots. You need JavaScript enabled to view it.';document.getElementById('cloak5dbb48d2a302676f8d3536c8eef6c21c').innerHTML += ''+addy_text5dbb48d2a302676f8d3536c8eef6c21c+'<\/a>'; |
| Last Trade: | US$1.11 |
| Daily Change: | -0.05 -4.31 |
| Daily Volume: | 42,084 |
| Market Cap: | US$20.930M |
March 06, 2025 March 03, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
